|
New Products
|
|
|
Just another MAO-B inhibitor with no proven advantages
|
|
|
|
|
|
Co-administered with trastuzumab: no benefit but more adverse effects
|
|
|
|
|
|
Longer survival confirmed, but cardiac risks to be monitored
|
|
|
|
|
|
|
Inadequately evaluated harms
|
|
|
|
|
|
|
|
|
|
Reviews
|
|
|
Treatment is problematic
|
|
|
|
|
|
|
|
|